S200: IMPROVED OVERALL SURVIVAL WITH FIRST-LINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: 6-YEAR ANALYSIS OF ECHELON-1
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000843692.94815.d7 |
| _version_ | 1797287227795963904 |
|---|---|
| author | M. Hutchings S. M. Ansell D. J. Straus J. M. Connors W. S. Kim A. Gallamini R. Ramchandren J. W. Friedberg R. Advani A. M. Evens P. Smolewski K. J. Savage N. L. Bartlett H.-S. Eom J. S. Abramson C. Dong F. Campana K. Fenton M. Puhlmann J. Radford |
| author_facet | M. Hutchings S. M. Ansell D. J. Straus J. M. Connors W. S. Kim A. Gallamini R. Ramchandren J. W. Friedberg R. Advani A. M. Evens P. Smolewski K. J. Savage N. L. Bartlett H.-S. Eom J. S. Abramson C. Dong F. Campana K. Fenton M. Puhlmann J. Radford |
| author_sort | M. Hutchings |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:29:54Z |
| format | Article |
| id | doaj.art-57605bd2f1244e37bd90726208823d0b |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:29:54Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-57605bd2f1244e37bd90726208823d0b2024-03-02T06:40:43ZengWileyHemaSphere2572-92412022-06-01610110210.1097/01.HS9.0000843692.94815.d7202206003-00101S200: IMPROVED OVERALL SURVIVAL WITH FIRST-LINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: 6-YEAR ANALYSIS OF ECHELON-1M. Hutchings0S. M. Ansell1D. J. Straus2J. M. Connors3W. S. Kim4A. Gallamini5R. Ramchandren6J. W. Friedberg7R. Advani8A. M. Evens9P. Smolewski10K. J. Savage11N. L. Bartlett12H.-S. Eom13J. S. Abramson14C. Dong15F. Campana16K. Fenton17M. Puhlmann18J. Radford191 Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark2 Division of Hematology, Mayo Clinic, Rochester, MN3 Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America4 BC Cancer Centre for Lymphoid Cancer and Department of Medical Oncology, Vancouver, Canada5 Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea6 Research and Innovation, Antoine-Lacassagne Cancer Centre, Nice, France7 The University of Tennessee Graduate School of Medicine, Knoxville, TN8 James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY9 Department of Medicine, Division of Oncology, Stanford University, Stanford, CA10 Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States of America11 Department of Experimental Hematology, Medical University of Lodz, Lodz, Poland4 BC Cancer Centre for Lymphoid Cancer and Department of Medical Oncology, Vancouver, Canada12 Washington University School of Medicine Siteman Cancer Center, St Louis, MO, United States of America13 Center for Hematologic Malignancy, National Cancer Center, Goyang, South Korea14 Massachusetts General Hospital, Boston, MA15 Takeda Development Center Americas, Inc. (TDCA), Lexington MA15 Takeda Development Center Americas, Inc. (TDCA), Lexington MA16 Seagen Inc., Bothell, WA, United States of America16 Seagen Inc., Bothell, WA, United States of America17 The University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdomhttp://journals.lww.com/10.1097/01.HS9.0000843692.94815.d7 |
| spellingShingle | M. Hutchings S. M. Ansell D. J. Straus J. M. Connors W. S. Kim A. Gallamini R. Ramchandren J. W. Friedberg R. Advani A. M. Evens P. Smolewski K. J. Savage N. L. Bartlett H.-S. Eom J. S. Abramson C. Dong F. Campana K. Fenton M. Puhlmann J. Radford S200: IMPROVED OVERALL SURVIVAL WITH FIRST-LINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: 6-YEAR ANALYSIS OF ECHELON-1 HemaSphere |
| title | S200: IMPROVED OVERALL SURVIVAL WITH FIRST-LINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: 6-YEAR ANALYSIS OF ECHELON-1 |
| title_full | S200: IMPROVED OVERALL SURVIVAL WITH FIRST-LINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: 6-YEAR ANALYSIS OF ECHELON-1 |
| title_fullStr | S200: IMPROVED OVERALL SURVIVAL WITH FIRST-LINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: 6-YEAR ANALYSIS OF ECHELON-1 |
| title_full_unstemmed | S200: IMPROVED OVERALL SURVIVAL WITH FIRST-LINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: 6-YEAR ANALYSIS OF ECHELON-1 |
| title_short | S200: IMPROVED OVERALL SURVIVAL WITH FIRST-LINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: 6-YEAR ANALYSIS OF ECHELON-1 |
| title_sort | s200 improved overall survival with first line brentuximab vedotin plus chemotherapy in patients with stage iii iv classical hodgkin lymphoma 6 year analysis of echelon 1 |
| url | http://journals.lww.com/10.1097/01.HS9.0000843692.94815.d7 |
| work_keys_str_mv | AT mhutchings s200improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithstageiiiivclassicalhodgkinlymphoma6yearanalysisofechelon1 AT smansell s200improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithstageiiiivclassicalhodgkinlymphoma6yearanalysisofechelon1 AT djstraus s200improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithstageiiiivclassicalhodgkinlymphoma6yearanalysisofechelon1 AT jmconnors s200improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithstageiiiivclassicalhodgkinlymphoma6yearanalysisofechelon1 AT wskim s200improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithstageiiiivclassicalhodgkinlymphoma6yearanalysisofechelon1 AT agallamini s200improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithstageiiiivclassicalhodgkinlymphoma6yearanalysisofechelon1 AT rramchandren s200improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithstageiiiivclassicalhodgkinlymphoma6yearanalysisofechelon1 AT jwfriedberg s200improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithstageiiiivclassicalhodgkinlymphoma6yearanalysisofechelon1 AT radvani s200improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithstageiiiivclassicalhodgkinlymphoma6yearanalysisofechelon1 AT amevens s200improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithstageiiiivclassicalhodgkinlymphoma6yearanalysisofechelon1 AT psmolewski s200improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithstageiiiivclassicalhodgkinlymphoma6yearanalysisofechelon1 AT kjsavage s200improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithstageiiiivclassicalhodgkinlymphoma6yearanalysisofechelon1 AT nlbartlett s200improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithstageiiiivclassicalhodgkinlymphoma6yearanalysisofechelon1 AT hseom s200improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithstageiiiivclassicalhodgkinlymphoma6yearanalysisofechelon1 AT jsabramson s200improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithstageiiiivclassicalhodgkinlymphoma6yearanalysisofechelon1 AT cdong s200improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithstageiiiivclassicalhodgkinlymphoma6yearanalysisofechelon1 AT fcampana s200improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithstageiiiivclassicalhodgkinlymphoma6yearanalysisofechelon1 AT kfenton s200improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithstageiiiivclassicalhodgkinlymphoma6yearanalysisofechelon1 AT mpuhlmann s200improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithstageiiiivclassicalhodgkinlymphoma6yearanalysisofechelon1 AT jradford s200improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithstageiiiivclassicalhodgkinlymphoma6yearanalysisofechelon1 |